Blue Jet Healthcare Limited has made the audio recording of its quarterly earnings conference call publicly available, concluding its disclosure obligations for the first quarter of FY27. The call, held on Monday, August 3, 2026, at 5:30 PM IST, focused on the company’s unaudited standalone financial results for the quarter ended June 30, 2026. This update ensures stakeholders have direct access to management’s commentary on operational performance and financial health.

The company notified both BSE Limited and the National Stock Exchange of India Limited regarding the submission of the audio recording on August 3, 2026. This action complies with Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sweta Poddar, Company Secretary & Compliance Officer, signed off on the communication, confirming the recording is hosted on the company’s official investor relations portal.

Conference Call Access Details

Investors and analysts can access the full recording via the link provided on the company’s website. The original live event allowed participants to join via universal access numbers or international toll-free lines. Management representatives were available to address queries regarding the financial results and operational updates. Participants were advised to dial in 10 minutes before the scheduled start time to ensure timely entry.

Management Representation

The following executives represented Blue Jet Healthcare during the earnings discussion, providing insights into the company’s strategic direction and financial outcomes:

• Shiven Arora, Managing Director
• V.K. Singh, Chief Operating Officer
• Ganesh Karuppannan, Chief Financial Officer
• Sanjay Sinha, Deputy Chief Financial Officer

About Blue Jet Healthcare

Blue Jet Healthcare operates as a specialty pharmaceutical and healthcare ingredient company under a contract development and manufacturing organization (CDMO) business model. The firm specializes in contrast media intermediates and high-intensity sweeteners, serving global innovator and multinational generic pharmaceutical companies through multi-year contracts. Key clients include GE Healthcare, Guerbet, Bracco, Colgate Palmolive (India) Limited, and Unilever.

Akshay Bansarilal Arora, promoter of blue jet healthcare , has declared that no encumbrance was created on the equity holdings of himself and associated persons acting in concert (PACs) during the financial year ended March 31, 2026. The declaration confirms that the promoter group’s stake of 79.81% remains free of any charges or pledges, ensuring stability in the company’s ownership structure for investors. This filing is a mandatory annual compliance under SEBI regulations, providing transparency regarding the security status of promoter-held shares.

The disclosure was submitted pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Akshay Bansarilal Arora signed the declaration on April 7, 2026, in Navi Mumbai, affirming that the information provided is true and correct. The regulation requires substantial shareholders to annually declare whether any encumbrance has been created on their shareholdings directly or indirectly.

Shareholding Structure of Promoters and PACs

The declaration covers the equity holdings of Akshay Bansarilal Arora and five other entities classified as promoters or part of the promoter group. The table below details the number of shares held and the corresponding percentage of voting capital for each entity as disclosed in the filing.

Analysis of Promoter Holdings

The data reveals a highly concentrated ownership structure, with Akshay Bansarilal Arora holding the majority stake at 62.80%. His son, Shiven Akshay Arora, and daughter, Archana Akshay Arora, hold significant portions at 10.96% and 6.05% respectively, indicating family-controlled governance. The remaining three entities—Alka Rakesh Bakshi, Amit Dhawan, and Anisha Juneja—are categorized as part of the promoter group but hold negligible stakes of only 10 shares each, contributing 0.00% to the total voting capital. The absence of any new encumbrances suggests that the promoters are not leveraging their shareholdings for external funding during this period, which is generally viewed as a positive signal for corporate governance and financial stability.